Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Trastuzumab deruxtecan
Related studies linked through entity extraction aliases.
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trastuzumab Deruxtecan in Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
DESTINY-PANTUMOUR04
- Status
- RECRUITING
- Phase
- N/A
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3